Clinical research and characteristic analysis of patients with advanced colorectal cancer treated with Yinyang Gongji Pills and capecitabine.
10.19540/j.cnki.cjcmm.20241126.502
- Author:
Lei WANG
1
;
Chao-Yue YAO
1
;
Jie-Ru ZHAN
1
;
Xiao-Xia SUN
1
;
Zhong-Xin YU
2
;
Xiao-Ya LIANG
3
;
Jian WANG
3
;
Xue GONG
1
;
Da-Rong WEI
1
Author Information
1. Chongqing University Three Gorges Hospital Chongqing 404000, China.
2. Chongqing Yunyang County Second People's Hospital Chongqing 404500, China.
3. Chongqing Yunyang Hospital of Traditional Chinese Medicine Chongqing 404500, China.
- Publication Type:English Abstract
- Keywords:
Yinyang Gongji Pills;
advanced colorectal cancer;
beneficial characteristic;
capecitabine
- MeSH:
Humans;
Capecitabine/adverse effects*;
Colorectal Neoplasms/mortality*;
Drugs, Chinese Herbal/adverse effects*;
Male;
Middle Aged;
Female;
Aged;
Adult;
Treatment Outcome
- From:
China Journal of Chinese Materia Medica
2025;50(5):1404-1411
- CountryChina
- Language:Chinese
-
Abstract:
Yinyang Gongji Pills have the effects of strengthening the body resistance to eliminate pathogenic factors, removing stasis, and reducing swelling, which is a commonly used traditional Chinese medicine(TCM) formula for treating intestinal accumulation. A real-world, registered, and single-arm clinical trial was conducted to observe the clinical efficacy and safety of Yinyang Gongji Pills combined with capecitabine in the treatment of advanced colorectal cancer and analyze the clinical characteristics of the patients. A total of 60 patients with advanced colorectal cancer who refused or could not tolerate standard treatment of western medicine were included in the study. They were treated with Yinyang Gongji Pills combined with capecitabine until disease progression or intolerable adverse events occurred. The main observation indicators were progression-free survival(PFS) and safety. The treatment effects of the patients under different baseline characteristics were analyzed. The clinical trial has found that the median PFS of all enrolled patients was 7.3 months, with 30.1% of patients having a PFS exceeding 12.0 months. Layered analysis showed that the median PFS of patients with the onset site being the colon and rectum were respectively 8.4 and 4.7 months. The median PFS of patients with high, medium, and low tumor burden were respectively 7.0, 4.7, and 10.8 months. The median PFS of patients with wild-type and mutant-type RAS/BRAF were respectively 7.9 and 6.9 months. The median PFS of patients with KPS scores ≥80 and ≤70 were respectively 7.9 and 6.5 months. The median PFS of patients treated with Yinyang Gongji Pills for ≥6, 3-6, and ≤3 months were respectively 8.0, 5.2, and 4.2 months. The median PFS of patients with spleen, kidney, liver, and lung syndrome differentiation in TCM were respectively 8.3, 6.7, 7.3, and 5.6 months. The median PFS of patients with TCM pathological factors including phlegm, dampness, and blood stasis were respectively 7.0, 7.3, and 6.5 months. Common adverse reactions include anemia, decreased white blood cells, decreased appetite, fatigue, and hand foot syndrome, with incidence rates being respectively 44.2%, 34.6%, 42.3%, 32.7%, and 17.3%. The results showed that the combination of Yinyang Gongji Pills and capecitabine demonstrated potential clinical efficacy and good safety in this study. The patients have clinical characteristics such as low tumor burden, onset site at the colon, KPS scores ≥ 80, long duration of oral TCM, and TCM syndrome differentiation including spleen or liver.
